Skip to main content
Caplight Logo









Touchlight

Touchlight

Private
HamptonHealthcare & Life Scienceshttps://touchlight.com/

Last Round

Grant

May 9, 2024

Est. Valuation

$1B

Total Funding Raised

$133.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Touchlight is a biotechnology company that provides enzymatic DNA manufacturing services and proprietary doggybone DNA (dbDNA) technology to support the development of genetic medicines, including mRNA, viral vectors, and vaccines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

enzymatic DNA synthesisdoggybone DNAdbDNAcell-free DNA productionCDMOsynthetic DNADNA manufacturinggenetic medicineadvanced therapyplasmid DNA alternativeDNA synthesis kitbiotech supply chainbenchtop DNA synthesisDNA platformbioprocessing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Touchlight Comparables

Compare Touchlight with similar companies based on industry and business-model similarity.

Touchlight comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Elegen
79%
Telesis Bio
76%
GenScript
73%

Touchlight Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 9, 2024
GrantMar 29, 2023
GrantDec 1, 2022
VC RoundSep 15, 2021
Series BMar 11, 2021
Grant
Mar 1, 2018

Key People

Founding team and executive leadership

Jonny Ohlson

Chair Group CEO, CEO, Executive Chair

Executive Team

Karen Fallen

Chief Executive Officer

Executive Team

Lauren Birchard

PA To CEO Office Manager

Executive Team

Alistair Howes

Chief Financial Officer

Executive Team

Touchlight Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2026

    Developing a hepatitis B/D vaccine in partnership with SVF Vaccines.

  • Apr 9, 2026

    Partnering with SVF Vaccines to advance hepatitis B/D vaccine.

Touchlight Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Touchlight Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Touchlight's valuation, stock price, and market status.

Firmographic Details

HeadquartersHampton
Employee Range161
Year Founded2007
Last FundingMay 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?